Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504517 | 1.00 | NPC1 (0.32) | NPC1SCN9A | |
| SCHEMBL2510702 | 0.94 | NPC1 (0.30) | NPC1 | |
| SCHEMBL2308305 | 0.94 | NPC1 (0.30) | NPC1 | |
| SCHEMBL2508235 | 0.90 | — | — | |
| SCHEMBL2304186 | 0.90 | — | — | |
| SCHEMBL2309407 | 0.89 | NPC1 (0.37) | NPC1SCN9A | |
| SCHEMBL2306761 | 0.88 | LRRK2 (0.31) | — | |
| SCHEMBL2507255 | 0.88 | LRRK2 (0.31) | — | |
| SCHEMBL2312761 | 0.87 | KDM4E (0.34) | — | |
| SCHEMBL2508315 | 0.87 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350077-B1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS LTD (GB) | 2016-01-27 | — | — | EP | disclosed |
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | ENTASIS THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-9040528-B2 | Chemical compounds 542 | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | ASTRAZENECA AB (SE) | 2014-05-08 | — | — | US | disclosed |
| US-8658641-B2 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2014-02-25 | — | — | US | disclosed |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| EP-2350077-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043893-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | NPC1 148/4885SCN9A 2808/4885 |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | SDHB, SDHA, RORC | NPC1 309/4885SCN9A 3178/4885 |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | NPC1 148/4885SCN9A 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.